NAD Chemical
NAD+ under changing conditions
A chemical name looks wonderfully definite. The human questions get messier: where was NAD+ measured, and what happened to the person?
NAD+ the chemical
I appreciate the satisfying precision of a reagent label. NAD+ has a full name, nicotinamide adenine dinucleotide, and a particular chemical form. Inside a cell, however, the interesting thing is how much work it does: it carries electrons through energy metabolism and supplies enzymes involved in DNA repair. A coenzyme is a small helper molecule that lets an enzyme do its work. This one has a crowded job description.
The plus sign identifies the oxidized form; accepting electrons turns it into NADH. Cells also spend NAD+ and rebuild it from smaller materials, including members of the vitamin B3 family. I enjoy the sheer thrift of this recycling chemistry. A body is continually remaking what it spends.
NAD+ is a dinucleotide. Peptides are chains of amino acids. The two may share space on a wellness page, but their chemistry is quite different.
Can you test NAD levels?
Yes. Human trials have measured NAD+ in whole blood before and during precursor supplementation. NR, short for nicotinamide riboside, and NMN, nicotinamide mononucleotide, are starting materials the body can use to make NAD+. Most of the controlled pill evidence concerns these precursors.
The distinction becomes very concrete in a trial of older adults with mild cognitive impairment: blood NAD+ rose 2.6-fold versus baseline while cognitive performance showed no significant improvement. I admire the experiment for letting the memory score spoil the tidy story. The chemical measurement worked; the hoped-for cognitive result remained elusive.
NAD+ levels blood test
A blood test answers a question about the sample taken. In the NR trial in healthy overweight adults, researchers recorded whole-blood NAD+ rises of 22%, 51%, and 142% in the groups given 100, 300, and 1000 mg/day for 8 weeks. Those are study results, with a named chemical, population and duration attached.
A personal target for longevity would require a further connection between the reading and a lasting health outcome. The 2025 review of human ageing trials describes limited efficacy and sparse tissue-specific data. I grant a blood result that narrower job.
Brain measurements tell another part of the story. The brain collection follows the scan result alongside the memory test.
Human NMN findings
Some results reach beyond the blood tube. NMN improved muscle insulin sensitivity in prediabetic, postmenopausal women, with no change in body composition or HbA1c. Another NMN trial in healthy middle-aged adults reported better walking distance. Each deserves its own examination.
The NR and NMN trial pages give those findings space; the study amounts stay attached to the experiments that used them.
The IV record
The IV story reaches back to an addiction case series reported in 1961. Its long history surprised me. The controlled evidence remains thin, and IV NAD+ has no FDA-approved treatment indication. The IV NAD therapy record brings the historical reports, extracellular chemistry and compounding risks together.